盐酸阿考替胺片治什么病,有什么效果？

It is a new type of gastric motility drug, a muscarinic receptor antagonist and a cholinesterase inhibitor, which can significantly improve the symptoms of patients with functional dyspepsia (FD). This drug was initiated by Japan's Zari Shinyaku Co., Ltd. and jointly developed with Japan's Astellas Pharmaceutical Company. It was finally approved in Japan in March 2013, with the registered name Acofide, and was launched in Japan in June 2013. It became the world's first drug for the treatment of FD diagnosed according to Rome III standards. The drug has good therapeutic effects. Let's take a closer look at it.

functional dyspepsia

Functional gastrointestinal disease is a common chronic disorder characterized by gastrointestinal symptoms but no evidence of underlying structural, organic, or metabolic disease on routine clinical examination. Functional dyspepsia (FD) is a common functional gastrointestinal disease, which refers to a symptomatic functional disorder originating from the gastroduodenal region. Its main symptoms are early satiety, postprandial abdominal pain and epigastric pain. FD accounts for more than one-third of gastroenterology specialty outpatient visits, with a prevalence of 20% to 40% in Western countries and 18.9% to 19.8% in Chinese community populations.

The therapeutic effect of acotiamide tablets

Shinozaki et al retrospectively analyzed 51 patients treated with acotiamide and found that acotiamide could improve the symptoms of FD patients. At 1 month and 3 months of treatment, the overall symptom improvement rates were 61% and 80%, respectively, and the complete symptom remission rates were 17% and 33%, respectively. Acotiamide had an early effect on the improvement rate and remission rate of symptoms of upper abdominal pain syndrome at 1 month, with an improvement rate of 63% and a remission rate of 42%, and at 3 months it was 69% and 39% respectively; the symptom improvement rate and remission rate of acotiamide for postprandial discomfort syndrome were 56% and 17% respectively at 1 month, and significantly increased to 78% and 46% at 3 months. This study suggests that acotiamide can improve the symptoms of upper abdominal pain syndrome and postprandial discomfort syndrome, and the effect is very good.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.

Recommended hot articles: